Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Isoquercitrin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : FDA
Deal Size : Undisclosed
Deal Type : Agreement
Quercis Announces Special Protocol Assessment Agreement with U.S. Food and Drug Administration
Details : SPA supports protocol for Phase 3 Trial of Isoquercetin to effect thromboembolic events in metastatic pancreatic cancer patients. Isoquercetin employs a novel pathway that is based on a new mechanism of action to prevent or reverse thrombus formation.
Product Name : ISQ950AN
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 05, 2021
Lead Product(s) : Isoquercitrin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : FDA
Deal Size : Undisclosed
Deal Type : Agreement